

NYRx Reminder to Providers: Aripiprazole, Quetiapine, and Risperidone Diagnosis Requirements

NYRx Preferred Drug List

Aripiprazole, quetiapine, and risperidone are preferred drugs in the Antipsychotics – Second Generation drug class in the [NYRx Preferred Drug List \(PDL\)](#) and are subject to prior authorization (PA) requirements as outlined on the PDL.

To reduce the need to obtain a PA, prescribers should ensure that they practice timely billing with appropriate ICD10 codes to be captured within the patient's Medicaid claim history and adhere to the criteria requirements listed in the [NYRx Preferred Drug List \(PDL\)](#).

If a PA is needed, prescribers can utilize the ***NEW*** [NYRx the Medicaid Pharmacy Program Atypical Antipsychotics \(AAP\) Prior Authorization Worksheet](#) to ensure all necessary clinical information is submitted with the request.

Prior Authorization Diagnosis Requirements

Aripiprazole, quetiapine, and risperidone require confirmation of an FDA-approved or compendia-supported diagnosis.

Note: Sleep disorders, including insomnia, as well as Disruptive Mood Dysregulation Disorder (DMDD) are not FDA-approved or compendia-supported diagnoses for aripiprazole, quetiapine, or risperidone.

Additional prior authorization requirements may apply as outlined in the [NYRx Preferred Drug List \(PDL\)](#).

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)
- [NYRx Preferred Drug Quick List](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.